{"id":42392,"date":"2025-09-28T11:16:31","date_gmt":"2025-09-28T03:16:31","guid":{"rendered":"https:\/\/flcube.com\/?p=42392"},"modified":"2025-09-28T11:16:32","modified_gmt":"2025-09-28T03:16:32","slug":"beijing-unicets-qh104a-receives-chinese-nmpa-approval-for-cns-solid%e2%80%91tumor-clinical-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42392","title":{"rendered":"Beijing Unicet\u2019s QH104A Receives Chinese NMPA Approval for CNS Solid\u2011Tumor Clinical Trials"},"content":{"rendered":"\n<p><strong>Beijing Unicet Biotechnology Co., Ltd.<\/strong> announced that its pioneering <strong>QH104A<\/strong>\u2014the world\u2019s first B7H3\u2011targeted, off\u2011the\u2011shelf allogeneic CAR\u2011\u03b3\u03b4 T\u2011cell therapy\u2014has obtained implicit approval for clinical trials from the <strong>Center for Drug Evaluation (CDE)<\/strong> of China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong>. The therapy is slated to treat recurrent or progressive malignant tumors of the central nervous system (CNS).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-why-qh104a-is-a-breakthrough\">Why QH104A Is a Breakthrough<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual\u2011Market Regulatory Milestone<\/strong>: QH104A is the first allogeneic cell therapy for solid tumors to secure simultaneous regulatory submissions and approvals in both <strong>China and the United States<\/strong>.<\/li>\n\n\n\n<li><strong>Targeted Antigen<\/strong>: It uniquely targets <strong>B7H3<\/strong>, a cell surface protein overexpressed in a wide range of CNS malignancies, offering a precision\u2011medicine approach rarely seen in solid\u2011tumor immunotherapy.<\/li>\n\n\n\n<li><strong>CAR\u2011\u03b3\u03b4 Synergy<\/strong>: By combining the innate antigen\u2011recognition of \u03b3\u03b4 T cells with the precision of CAR technology, the therapy delivers deeper, more sustained tumor\u2011cell killing while preserving off\u2011target safety.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-clinical-and-commercial-implications\">Clinical and Commercial Implications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Off\u2011the\u2011Shelf Advantage<\/strong>: The \u201coff\u2011the\u2011shelf\u201d design eliminates the need for patient\u2011specific manufacturing, reducing turnaround time and cost\u2014critical factors for treating aggressive CNS tumors.<\/li>\n\n\n\n<li><strong>Global Positioning<\/strong>: With approvals in both major regulatory jurisdictions, QH104A is poised to become a first\u2011in\u2011class option for clinicians worldwide seeking novel solutions for hard\u2011to\u2011treat CNS malignancies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Beijing Unicet Biotechnology Co., Ltd. announced that its pioneering QH104A\u2014the world\u2019s first B7H3\u2011targeted, off\u2011the\u2011shelf allogeneic&#8230;<\/p>\n","protected":false},"author":1,"featured_media":42394,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,93],"tags":[16,21,77,4373],"class_list":["post-42392","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-digital","tag-cancer","tag-car-t","tag-cell-therapy","tag-unicet-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Beijing Unicet\u2019s QH104A Receives Chinese NMPA Approval for CNS Solid\u2011Tumor Clinical Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing Unicet Biotechnology Co., Ltd. announced that its pioneering QH104A\u2014the world\u2019s first B7H3\u2011targeted, off\u2011the\u2011shelf allogeneic CAR\u2011\u03b3\u03b4 T\u2011cell therapy\u2014has obtained implicit approval for clinical trials from the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The therapy is slated to treat recurrent or progressive malignant tumors of the central nervous system (CNS).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42392\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Beijing Unicet\u2019s QH104A Receives Chinese NMPA Approval for CNS Solid\u2011Tumor Clinical Trials\" \/>\n<meta property=\"og:description\" content=\"Beijing Unicet Biotechnology Co., Ltd. announced that its pioneering QH104A\u2014the world\u2019s first B7H3\u2011targeted, off\u2011the\u2011shelf allogeneic CAR\u2011\u03b3\u03b4 T\u2011cell therapy\u2014has obtained implicit approval for clinical trials from the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The therapy is slated to treat recurrent or progressive malignant tumors of the central nervous system (CNS).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42392\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-28T03:16:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-28T03:16:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2804.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42392#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42392\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Beijing Unicet\u2019s QH104A Receives Chinese NMPA Approval for CNS Solid\u2011Tumor Clinical Trials\",\"datePublished\":\"2025-09-28T03:16:31+00:00\",\"dateModified\":\"2025-09-28T03:16:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42392\"},\"wordCount\":244,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42392#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2804.webp\",\"keywords\":[\"Cancer\",\"CAR-T\",\"Cell-therapy\",\"Unicet Biotechnology\"],\"articleSection\":[\"Company\",\"Digital\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42392#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42392\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42392\",\"name\":\"Beijing Unicet\u2019s QH104A Receives Chinese NMPA Approval for CNS Solid\u2011Tumor Clinical Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42392#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42392#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2804.webp\",\"datePublished\":\"2025-09-28T03:16:31+00:00\",\"dateModified\":\"2025-09-28T03:16:32+00:00\",\"description\":\"Beijing Unicet Biotechnology Co., Ltd. announced that its pioneering QH104A\u2014the world\u2019s first B7H3\u2011targeted, off\u2011the\u2011shelf allogeneic CAR\u2011\u03b3\u03b4 T\u2011cell therapy\u2014has obtained implicit approval for clinical trials from the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The therapy is slated to treat recurrent or progressive malignant tumors of the central nervous system (CNS).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42392#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42392\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42392#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2804.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2804.webp\",\"width\":1080,\"height\":608,\"caption\":\"Beijing Unicet\u2019s QH104A Receives Chinese NMPA Approval for CNS Solid\u2011Tumor Clinical Trials\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42392#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Beijing Unicet\u2019s QH104A Receives Chinese NMPA Approval for CNS Solid\u2011Tumor Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Beijing Unicet\u2019s QH104A Receives Chinese NMPA Approval for CNS Solid\u2011Tumor Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","description":"Beijing Unicet Biotechnology Co., Ltd. announced that its pioneering QH104A\u2014the world\u2019s first B7H3\u2011targeted, off\u2011the\u2011shelf allogeneic CAR\u2011\u03b3\u03b4 T\u2011cell therapy\u2014has obtained implicit approval for clinical trials from the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The therapy is slated to treat recurrent or progressive malignant tumors of the central nervous system (CNS).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42392","og_locale":"en_US","og_type":"article","og_title":"Beijing Unicet\u2019s QH104A Receives Chinese NMPA Approval for CNS Solid\u2011Tumor Clinical Trials","og_description":"Beijing Unicet Biotechnology Co., Ltd. announced that its pioneering QH104A\u2014the world\u2019s first B7H3\u2011targeted, off\u2011the\u2011shelf allogeneic CAR\u2011\u03b3\u03b4 T\u2011cell therapy\u2014has obtained implicit approval for clinical trials from the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The therapy is slated to treat recurrent or progressive malignant tumors of the central nervous system (CNS).","og_url":"https:\/\/flcube.com\/?p=42392","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-28T03:16:31+00:00","article_modified_time":"2025-09-28T03:16:32+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2804.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42392#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42392"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Beijing Unicet\u2019s QH104A Receives Chinese NMPA Approval for CNS Solid\u2011Tumor Clinical Trials","datePublished":"2025-09-28T03:16:31+00:00","dateModified":"2025-09-28T03:16:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42392"},"wordCount":244,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42392#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2804.webp","keywords":["Cancer","CAR-T","Cell-therapy","Unicet Biotechnology"],"articleSection":["Company","Digital"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42392#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42392","url":"https:\/\/flcube.com\/?p=42392","name":"Beijing Unicet\u2019s QH104A Receives Chinese NMPA Approval for CNS Solid\u2011Tumor Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42392#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42392#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2804.webp","datePublished":"2025-09-28T03:16:31+00:00","dateModified":"2025-09-28T03:16:32+00:00","description":"Beijing Unicet Biotechnology Co., Ltd. announced that its pioneering QH104A\u2014the world\u2019s first B7H3\u2011targeted, off\u2011the\u2011shelf allogeneic CAR\u2011\u03b3\u03b4 T\u2011cell therapy\u2014has obtained implicit approval for clinical trials from the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The therapy is slated to treat recurrent or progressive malignant tumors of the central nervous system (CNS).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42392#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42392"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42392#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2804.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2804.webp","width":1080,"height":608,"caption":"Beijing Unicet\u2019s QH104A Receives Chinese NMPA Approval for CNS Solid\u2011Tumor Clinical Trials"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42392#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Beijing Unicet\u2019s QH104A Receives Chinese NMPA Approval for CNS Solid\u2011Tumor Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2804.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42392"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42392\/revisions"}],"predecessor-version":[{"id":42395,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42392\/revisions\/42395"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42394"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42392"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}